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ABSTRACT: Biodegradable poly(DL-lactic acid) (PLA) and poly(lactic-co-glycolic acid) 
(PLGA) microparticles with tunable size, shape, internal structure and surface morphology 
were produced by counter-current flow focusing in axisymmetric (3D) glass capillary 
devices. The dispersed phase was composed of 0.5-2 wt% polymer solution in a volatile 
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organic solvent (ethyl acetate or dichloromethane) and the continuous phase was 5 wt% 
aqueous poly(vinyl alcohol) solution. The droplets with a coefficient of variation in dripping 
regime below 2.5 % were evaporated to form polymeric particles with uniform sizes ranging 
between 4-30 µm. The particle microstructure and surface roughness were modified by 
adding nanofiller (montmorillonite nanoclay) or porogen (2-methylpentane) in the dispersed 
phase to form less porous polymer matrix or porous particles with golf-ball-like dimpled 
surface, respectively. The presence of 2-4 wt% nanoclay in the host polymer significantly 
reduced the release rate of paracetamol and prevented the early burst release, as a result of 
reduced polymer porosity and tortuous path for the diffusing drug molecules. Numerical 
modelling results using the volume of fluid-continuum surface force model agreed well with 
experimental behaviour and revealed trapping of nanoclay particles in the dispersed phase 
upstream of the orifice at low dispersed phase flow rates and for 4 wt% nanoclay content, due 
to vortex formation. Janus PLA/PCL (polycaprolactone) particles were produced by solvent 
evaporation-induced phase separation within organic phase droplets containing 3 % (v/v) 
PLA/PCL (30/70 or 70/30) mixture in dichloromethane. A strong preferential adsorption of 
Rhodamine 6G dye onto PLA was utilized to identify PLA portions of the Janus particles by 
Confocal Laser Scanning Microscopy (CLSM). Uniform hemispherical PCL particles were 
produced by dissolution of PLA domes with acetone.  
KEYWORDS: Microfluidic flow focusing, Biodegradable microspheres, Drug delivery 
systems, Poly(lactic acid), Poly(lactic-co-glycolic acid), Nanoclay, Janus particle, 
Hemispherical particle. 
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INTRODUCTION 
Conventional oral and intravenous drug administration routes are characterized by rapid drug 
release and absorption.1 Limitations such as poor patient compliance (due to missing or 
altering dosages) and difficulty in attainment of steady state conditions (as a result of peak-
valley plasma concentration fluctuations) have led to poor drug efficacy and toxicity as 
consequences of underdosing and overdosing of drugs respectively in patients.2 Drug delivery 
systems have been designed to overcome these limitations and extend, delay and target drug 
release3–6. When properly designed, controlled drug delivery systems should be able to 
deliver drugs at a predetermined rate and manner, either locally or systemically, for a specific 
period of time after drug administration, which can eliminate excessive fluctuations of drug 
plasma concentrations.7 
Biocompatible polymeric materials such as non-biodegradable hydrophobic polymers,8 
hydrogels,9 water soluble polymers,10 and synthetic biodegradable polymers have been 
widely used as vehicles for drug delivery.1 Biodegradable polymers have been mainly used in 
the form of microspheres, since they offer high surface area for adhesion and drug release and 
a low drag force during mobility in fluids.11 The most common biodegradable synthetic 
polymers are poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA)12, and 
polycaprolactone (PCL),1,13 due to their approval by FDA (Food and Drug Administration)14 
and environmentally friendly nature. In order to meet different dosage requirements, there is a 
strong need to modify drug solubility and release rate by incorporation of different additives 
into a host biodegradable polymer. 
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Nanoclays are FDA approved plate-like nanoparticles of layered mineral silicates that can be 
integrated into the polymer matrix to improve mechanical and rheological properties of 
polymeric microspheres and increase the solubility and bioavailability of drugs such as 
ibuprofen, indomethacin, diclofenac, naproxen, fenbufen, and paracetamol.2 Nanoclays also 
have highly desirable dietary, bacterial and metabolic detoxification characteristics15.  
Another method of modification of drug release kinetics is internal phase separation caused 
by addition of non-solvent in the mixture of polymer and solvent prior to emulsification. 
Depending on polymer to non-solvent ratio and the type of solvent, non-solvent and polymer, 
phase separation within emulsion droplets (triggered by solvent evaporation) can lead to 
core/shell, occluded, acorn or heteroaggregated particle morphology.16 Hole-shell and 
crescent-moon-shaped microparticles can be synthesised from acorn-shaped biphasic droplets 
by polymerisation of one of the phases.17,18 Such unique morphologies can modify drug 
release profile12,19,20 and increase the potential for alternative routes of drug administration. 
Emulsion-solvent evaporation is one of the most common methods for fabrication of 
polymeric microspheres from pre-formed polymers. Emulsification can be carried out using 
conventional top-down methods based on breaking larger droplets into smaller ones,21 such as 
mechanical agitation, high-pressure homogenization, and sonication or bottom-up methods, 
based on direct drop-by-drop generation, such as membrane emulsification22–24, microchannel 
emulsification,25 and microfluidic techniques.26–29 Conventional emulsification methods are 
energy intensive and often lead to polydispersed microspheres. Microfluidic methods allow 
production of particles with low polydispersity (CV = Standard Deviation/Mean < 3%) and 
high encapsulation efficiency that are perfectly tailored to meet the needs of pharmaceutical 
industry.30 However, microfluidic droplet generators are typically planar (2-D) and made 
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from single crystal silicon chips using expensive microfabrication methods31 or mouldable 
polymers such as polydimethylsiloxane (PDMS), which swell and deform in contact with 
organic solvents.29  
Here, we investigate formation of structured polymeric microspheres using glass capillary 
microfluidic devices. These devices pioneered by Utada et al.32 offer 3-D flow focusing that 
minimizes wetting, they are cheap to fabricate and more mechanically robust and inert than 
polymeric devices.33,13 Microstructural modifications of polymer matrix occurred due to 
introduction of nanoclay, non-solvent or second polymer, which resulted in the formation of 
composite and non-spherical particles and particles with structured surface (Figure 1b-d).  
 
Figure 1. Strategies used in this work for creation of polymer particles: (a) Plain polymer 
particle; (b) Nanoclay embedded polymer particle; (c) Golf ball-like particle; (d) Janus and 
hemispherical particle. 
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A special attention was paid on the effect of flow conditions on the retention (trapping) of 
suspended nanoparticles in the device. This phenomenon is important in all microfluidic 
processes where fluid streams entering a microfluidic channel contain suspended nano-
objects, such as colloidal particles, nano-assemblies, nanofibers, nanotubes or viruses. The 
effect of internal structure of the particles on the release rate of encapsulated drug was also 
discussed. Glass capillary devices have been used for fabrication of vesicles such as 
colloidosomes34, polymersomes,35 and liposomes,36 and microparticles such as solid lipid37 
and microgel33 particles.  
This paper presents new applications of glass capillary microfluidics for the production of 
drug delivery vehicles composed of nanoclay-embedded, golf ball-like, Janus, and 
hemispherical polymeric particles. A facile control over the particle size and morphology 
achieved in this work enables accurate prediction of drug release behavior.  
 
EXPERIMENTAL SECTION 
Materials. Poly(dl-lactic acid) (PLA, IngeoTM 4060D, Mw = 89,000 gmol-1) supplied by 
NatureWorks LLC (Minnetonka, MN, USA), poly(lactic-co-glycolic acid) (PLGA, Mw = 
10,000 g mol-1, 50% DL-lactic acid and 50% glycolic acid), supplied by Wako Pure Chemical 
Industries (Osaka, Japan) and polycaprolactone (PCL, Mw = 14,000 g mol−1) supplied by 
Sigma-Aldrich (UK) served as primary ingredients of the microspheres. Organically modified 
nanoclay (Cloisite ® 30B, ρ = 1980 kg m-3, Southern Clay Products, Gonzales, TX, USA) 
consisting of plate-like montmorillonite nanoparticles surface-substituted with alkyl 
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ammonium ions, was used as a polymer filler for the microspheres. Dichloromethane (DCM, 
HPLC grade, Fisher Scientific, UK) and ethyl acetate (Sigma-Aldrich, UK) were used as non-
polar polymer solvents. 2-Methylpentane (Sigma-Aldrich, UK) was added to the dispersed 
phase as a polymer non-solvent in the production of golf ball-like particles. Paracetamol (4-
acetamidophenol) obtained from Sigma-Aldrich was used for drug release experiments. 
Poly(vinyl alcohol) (PVA, Mw = 13,000-23,000, 87-89% hydrolyzed) supplied by Sigma-
Aldrich (UK) was used as a water-soluble stabilizer in the continuous phase. Reverse osmosis 
water was prepared using Millipore 185 Milli-Q Plus apparatus. Rhodamine 6G (Rh6G) and 
Nile red (Sigma-Aldrich, UK) were used as fluorescence dyes for identification of bifacial 
particle morphology. 2-[methoxy(polyethylenoxy)propyl]-trimethoxysilane (MPEOPS) 
supplied by Fluorochem Ltd (UK) was used to enhance hydrophilicity of inner capillary.  
Methods. Fabrication of Glass Capillary Device. A round capillary with inner diameter 0.58 
mm and outer diameter 1 mm (Intracel, UK) was pulled using a micropipette puller (Sutter 
Instrument Company, USA). The tip of the pulled capillary was polished to desired orifice 
size using an abrasive paper (Black Ice Waterproof T402 Paper, Alpine Abrasives, UK), 
cleaned with compressed air and Milli-Q water and treated with MPEOPS. A 150-mm long 
square capillary with an inner diameter of 1.05±0.1 mm (Atlantic International Technologies, 
USA) was cut with a pen cutter to a required length of 50 mm and attached to a microscopic 
slide using epoxy glue (5-Minute Epoxy® Devcon). The round capillary was then inserted in 
the square capillary and centred using an inverted microscope (XDS-3, GX Microscopes, 
UK) before it was glued to position. The exposed end of the round capillary was connected 
via PVC medical tubing (ID: 1.00 mm, OD: 1.05 mm; Fisher Scientific, UK) to collection 
 8 
vial. All fabrication steps were carried out in a dust-free environment and disposable medical 
gloves were worn to prevent contamination of the device. 
Production of emulsions and particles. The compositions of dispersed phase used in the 
production of different particles are shown in Table 1.  
Table 1. Composition of dispersed phase used in this work for preparation of different 
particles. The continuous phase was 5 wt% PVA in Milli-Q water in all formulations. 
 
Particle structure Dispersed phase composition wt% 
Plain polymer particles  Polymer (PLA or PLGA) Solvent (DCM or ethyl acetate) 
0.5, 1 or 2 
99.5, 99 or 98 
Nanoclay-embedded polymer 
particles  
Nanoclay 0.02 or 0.04 
Polymer (PLA or PLGA)  0.98 or 0.96 
Solvent (DCM or ethyl acetate) 99 
Golf ball-like polymer particles 
Nonsolvent (2-methylpentane) 
Polymer (PLA or PLGA) 
Solvent (DCM or ethyl acetate) 
0.3 or 3 
0.7 or 7 
99 or 90 
Janus polymer particles 
Polymer mixture (PCL + PLA) 3 
(PCL:PLA = 1:2 or 2:1 v/v)  
Solvent (DCM) 97 
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Figure 2. (a) Experimental setup of microfluidic device for the production and monitoring of 
microdroplet generation; (b) and (c) Monodispersed droplet generation in the dripping regime 
for a dispersed phase of PLA/nanoclay in DCM; (d) Polydispersed droplet generation in the 
jetting regime for dispersed phase of PLA in DCM. Scale bars: 250 μm. 
 
For droplet production, glass capillary device was placed on a GXM XD63 optical inverted 
microscope. The dispersed and continuous phase of desired formulation (Table 1) were 
delivered from two gas tight syringes with Luer-lock fitting (VWR Catalyst Company, UK) 
mounted on separate Harvard Apparatus 11 Elite syringe pumps (Figure 2). PTFE medical 
tubing (Smiths Medical International Ltd, UK) and polyethylene medical tubing (Fisher 
Scientific, UK) were used to deliver the dispersed and continuous phase respectively to the 
corresponding needle on the device. The continuous phase was delivered via a 3-way stop 
cock (VWR Catalyst Company, UK) and Puradisc syringe filter (Sigma-Aldrich Company, 
UK) for easy syringe refilling and removal of microscopic impurities in the liquid. The two 
phases were supplied within the device counter-currently at low flow rates, such that the 
oil/aqueous interface slowly approached the orifice of the inner capillary to avoid wetting the 
tip by the oil phase. Droplet formation occurred on adjustment flowrates with syringe pumps.  
Droplets were generated within a tapered section of the collection capillary (Figure 2 b-d). 
Real-time monitoring of droplet generation was achieved with a high speed camera (Phantom 
V9.0, Vision Research, USA) supported by the Phantom Camera Control (PCC) software 
(version 2.14.727.1, Vision Research, USA), which provided interface for image acquisition, 
brightness/contrast adjustment, and post-generation analysis. Generated droplets were 
collected in a vial and vacuum evaporated at room temperature to form particles.  
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Analysis of Video Recordings. Recorded videos of droplet generation were stored in the 
camera’s internal memory with the aid of the PCC software. The number of frames per 
second 𝑛𝑠 and the number of frames stored 𝑛𝑓 were chosen based on the storage space 
availability and droplet generation rate. The droplet generation frequency 𝑓 was calculated as: 
𝑓 = 𝑛𝑑𝑛𝑠/𝑛𝑓, where 𝑛𝑑 is the number of droplets generated in 𝑛𝑓/𝑛𝑠 seconds, determined 
using ImageJ v.1.44 software (Wayne Rasband, National Institute of Health). 
X-Ray Diffraction (XRD) Analysis. Wide angle X-ray diffraction patterns were obtained using 
a Bruker D2 Phaser diffractometer fitted with a 1-dimensional LynxEYETM detector. A 
copper X-ray source (Kα = 1.54184 Å) was used run at 30 kV and 10 mA, with Kβ radiation 
suppressed by means of a 0.5 mm thick nickel filter. Patterns were recorded over a 2θ range 
of 2-40o with a step size of 0.02o and an equivalent step time of 49.2 s. Sample rotation was 
set at 15 rpm. Bruker’s proprietary Eva 2.0 software was used to obtain the spectra.  
Scanning Electron Microscopy (SEM) and Focused Ion Beam (FIB) Imaging. Imaging was 
carried out using a dual-beam focused ion beam scanning electron microscope (FIB-SEM) 
(Nova 600 Nanolab, FEI Company, Hillsboro, Oregon, USA). All SEM imaging were carried 
out at 10 kV and 2.1 nA over a 30 µ aperture exposure.  
For FIB imaging 30 kV was used throughout. External angular imaging was initially obtained 
at 30 pA before an increase to 0.3 nA for a protective platinum (Pt) deposit. A cross-section 
was then obtained at 20 nA before cross section cleaning was carried out at 7 nA and reduced 
to 3nA for a final cleaning. Cleaning was necessary for better microstructural imaging. The 
current was finally reduced to 30 pA to preserve the exposed cross-sectional microstructure 
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and prevent modification due to beam exposure during imaging, which was carried out at 
approximately 2 min/image for noise reduction.  
Confocal Laser Scanning Microscopy (CLSM). The microstructure of Janus particles was 
vizualised using a Nikon Eclipse TE300 confocal inverted microscope connected to a 
computer running Zeiss LaserSharp 2000™ software. The Janus particles were stained with 
Rhodamine 6G and Nile Red, added to the dispersed phase prior to emulsification. A 
suspension of Janus particles to be scanned was placed on a microscopic slide and allowed to 
dry. The sample was excited with argon laser with a wavelength of 488 nm and helium-neon 
laser with a wavelength of 543 nm. The total emission was separated into two images 
captured by two photomultiplier tubes (PMTs): PMT1 captured fluorescence between 515±30 
nm (green region) and PMT2 captured fluorescence above 570 nm (yellow-red region). 
Cumulative Drug Release Study. 0.7 wt% of paracetamol (PCM) was added to the dispersed 
phase containing ethyl acetate (EA). The concentration of PCM in the continuous phase was 
measured using a Lambda 35 UV/Vis (PerkinElmer Instruments, UK) double beam 
spectrophotometer, supported by UVWINLAB version 2.85.04 software (PerkinElmer 
Instruments, UK), over 120 h at a wavelength of 242 nm. The solubility of PCM in EA and 
water is 10.7 and 17.4 g/kg, respectively.38 The cumulative release was determined by: 
                                𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 𝑟𝐶𝐶𝐶𝐶𝑟𝐶 = 𝐶𝐷𝐷𝐷𝐷
𝐶𝐷𝐷𝐷𝐷
0 × 100                                                               (1) 
where 𝐶𝐷𝐷𝐷𝐷 is the concentration of drug in the continuous phase and 𝐶𝐷𝐷𝐷𝐷0  is the predicted 
drug concentration in the continuous phase after complete release.  
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Governing Equations and Numerical Modelling. Numerical modelling of drop generation was 
carried out using a two-dimensional axisymmetric volume of fluid (VOF) approach.39 The 
following equations of mass, Eq. 2, and momentum conservation, Eq. 3, were used:  
𝜕𝜕
𝜕𝐶
+ 𝛻 ∙ �𝜕𝑈�⃗ � = 0                                                                  (2) 
𝜕
𝜕𝐶
�𝜕𝑈�⃗ � + 𝛻 ∙ �𝜕𝑈�⃗ 𝑈�⃗ � =  −𝛻𝛻 + 𝛻 ∙ �𝜇�𝛻𝑈�⃗ + 𝛻𝑈�⃗ 𝑇�� +  𝐹𝑏����⃗                                 (3) 
where 𝑈�⃗  and P are velocity and pressure and t, 𝜇, and 𝜕 are time, dynamic viscosity and 
density. The interfacial force, 𝐹𝛾, and gravitational force are included in the source term, 𝐹𝑏, 
However, since the length-scale is in the order of micro, the gravitational force is negligible 
and 𝐹𝑏����⃗ = 𝐹𝛾���⃗ . In VOF model, a momentum equation is solved for all phases and the advection 
of interface is tracked by solving a transport equation for volume fraction, 𝑓: 
𝜕𝑓
𝜕𝐶
+ 𝑈�⃗ .𝛻𝑓 = 0                                                                  (4) 
where f determines the portion of each cell filled with one of the two phases:  
f = 0  the cell is filled with aqueous phase  
0 < f < 1 fluid-fluid interface exists in the cell                 (5) 
f = 1 the cell is filled with oil phase  
The dynamic viscosity and density in the momentum equation, Eq. 3, were calculated by:     𝜇 = 𝑓 𝜇  𝑜 + (1 − 𝑓 )𝜇𝑤                                                             (6) 
𝜕 = 𝑓 𝜕 𝑜 + (1 − 𝑓 )𝜕 𝑤                                                             (7) 
where the subscripts o and w refer to oil and aqueous phases respectively. Continuum surface 
force (CSF) method40 was used to calculate the interfacial force term included in Eq. 3:  
 𝐹𝛾 =  𝛾𝛾𝛻𝑓                                                                          (8) 
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where γ is the interfacial tension and κ the local curvature of the interface, calculated as: 
𝛾 = 𝛻 ∙ 𝑛�                                                                             (9) 
where n�  is the unit normal defined as: 
𝑛� =   𝛻𝑓|𝛻𝑓|                                                                              (10) 
Equation 3 was solved using a pressure-based segregated algorithm in a finite-volume based 
commercial software Ansys® Fluent v. 15.0. Figure s.1 shows a schematic of the simulated 
geometry and the mesh used in the simulations. The discretised momentum equation was 
approximated by second order upwind scheme and the pressure term was interpolated using 
PRESTO scheme. The exact pressure was calculated on the cell faces in order to prevent 
interpolation error. The pressure-velocity coupling was achieved by SIMPLE scheme and the 
interpolation of interface was performed by Geo-Reconstruct algorithm. In order to reduce the 
computational cost, a variable time step method was used with Co = 0.35. A grid 
independence study was carried out by generating four meshes with resolutions of 8, 6, 4, and 
2 µm. Since the solutions for 4 and 2 µm were very similar, the resolution of 4 µm was 
selected for the simulations. A summary of the boundary conditions is listed in Table 2. 
 Table 2. Summary of the boundary conditions used in this work. 
 
 
 
 
 
Rheological Characterization. The densities of dispersed and continuous phases were 
determined at 25oC using a 10 ml pycnometer. The kinematic viscosity measurements were 
Boundary Type 
Inlets Mass flow inlet 
Outlet Pressure outlet 
Symmetry Axis Axis 
Wall No-slip wall 
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performed using a U-tube viscometer at 25oC. The interfacial tension was measured using a 
DSA100S drop shape analyzer (KRÜSS GmbH, Hamburg, Germany). The results are listed 
in Table 3. 
Table 3. Physical properties of dispersed and aqueous phase used for numerical validation. 
The interfacial tension was measured against 5 wt% aqueous solution of PVA. 
Phase Density at 298 K (kg dm-3) 
Viscosity at 
298 K (mPas) 
Interfacial 
tension (mNm-1) 
1 wt% PLGA in Ethyl Acetate 0.910 0.5 1.0 
1 wt% PLA/nanoclay (96:4) in DCM 1.283 1.3 2.2 
5 wt% PVA in water 1.020 4.0 - 
 
RESULTS AND DISCUSSION 
Production of Emulsions. Movie 1 in the supporting information shows a typical droplet 
generation behavior in dripping regime. Monodispersed droplets with a diameter of 130 µm 
were generated using orifice with 200 µm diameter. Droplets were stable against coalescence 
in the collection capillary. The droplet pinch off occurred at approximately one orifice 
diameter downstream of the orifice at the frequency of 410 Hz. The droplet size and 
generation frequency were controlled by manipulating the flowrates and varying the orifice 
diameter of the collection tube.  
Effect of Phase Flowrate Ratio. Figure 3 shows the effect of flow rate ratio, 𝑄𝑐/𝑄𝑑 on the 
average droplet diameter, 𝐷𝑑 for three different orifice diameters, 𝐷𝑜. The effect of 𝑄𝑐/𝑄𝑑 on 
the coefficient of variation of droplet sizes, 𝐶𝐶 and the droplet generation frequency, 𝑓 is 
shown on the same figure for 𝐷𝑜 = 200 µm. The dispersed phase was 1 wt% PLA/nanoclay 
mixture in DCM with a polymer to nanoclay ratio of 98/2 (w/w). 
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Figure 3. The effect of continuous to dispersed phase flow rate ratio, Qc/Qd on average 
droplet diameter, Dd in dripping regime:  Do = 224 μm, Qc = 12 ml h-1;  Do = 200 μm, Qc 
= 10 ml h-1;  Do = 100 μm, Qc = 5 ml h-1. The coefficients of variation of droplet sizes, CV 
(◊) and droplet generation frequencies, f (+) are shown for 200 μm orifice size only. The 
dotted line is for f. The dispersed phase is 1 wt% PLA/nanoclay (98/2) in DCM. 
 
The droplet size was found to decrease with an increase in the flow rate ratio. When the data 
were plotted as 𝐷𝑑/𝐷𝑜 vs. 𝑄𝑐/𝑄𝑑 on a log-log graph, a single master line was obtained for all 
orifice sizes with the following equation: 𝐷𝑑/𝐷𝑜 = 𝐴(𝑄𝑐/𝑄𝑑)𝐵, where 𝐴 = 1.23, 𝐵 = −0.41, 
and 𝑅2 = 0.940 (the graph not shown here). The 𝐵 value of −0.41 is very similar to −0.39 
found earlier for the dispersed phase composed of PLA in DCM,41 which means that the 
presence of nanoclay in DCM did not affect droplet generation. Droplet formation is a result 
of the balance between the detaching forces acting in the direction of flow (viscous drag and 
inertial force) and the interfacial tension force acting in the opposite direction. In dripping 
regime, which occurs at low flow rates of both phases, the main competition is between drag 
and interfacial tension force. A viscous drag force increases with increasing 𝑄𝑐/𝑄𝑑, as a 
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result of increase in the velocity gradient at the interface, causing the growing droplet to 
detach more quickly, which leads to smaller droplets and faster droplet generation (Figure 3). 
The ratio between viscous drag force exerted on the interface by the continuous phase and 
interfacial tension force is represented by the Capillary number of the continuous phase, 𝐶𝐶𝑐, 
given by 𝜇𝑐𝐶𝑐 𝜎𝑐⁄ , which is ranges between 0.003 and 0.006 for the conditions shown in 
Figure 3.  
The results in Figure 3 were obtained in dripping regime, which occurs at 3 < 𝑄𝑐/𝑄𝑑 < 30, 
but 𝑄𝑑 must be within a certain range. If 𝑄𝑑 is too low, droplet generation is unstable or non-
existing, irrespective of 𝑄𝑐/𝑄𝑑 value. If 𝑄𝑑 is too high, transition from dripping to widening 
jetting occurs and the droplet size is a result of the competition between inertial force of the 
dispersed phase and interfacial tension. The Weber number of the dispersed phase is the ratio 
between the inertial force of the dispersed phase and interfacial tension, 𝜎: 𝑊𝑑 = 𝜕𝑑𝐷𝑗𝐶𝑑2/𝜎, 
where 𝜕𝑑 is the dispersed phase density, 𝐷𝑗  is the jet diameter, and 𝐶𝑑 is the mean velocity of 
the dispersed phase. For the data shown in Figure 3, 𝑊𝐶𝑑 = 0.002-0.02.  
At 𝑄𝑐/𝑄𝑑 > 30, the dispersed phase forms a long narrow jet that breaks into polydispersed 
droplets further downstream (Figure 2d), which is known as the narrowing jetting regime.33 In 
contrast, dripping regime is characterised by highly uniform droplets with 𝐶𝐶< 3% (Figs. 2 b 
and c). In Figure 3, 𝐶𝐶 ranged from 0.8 to 2.5% for 𝐷𝑜 = 200 µm and similar 𝐶𝐶s were 
obtained in dripping regime for other orifice sizes and emulsion formulations.  
As shown in Figure 3 for the dispersed phase containing DCM, progressively smaller droplets 
were generated when the orifice diameter was reduced from 224 to 100 µm. This effect is 
illustrated for ethyl acetate on the images shown in Figure 4, where the orifice diameters of 
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200, 110, 70, and 40 µm resulted in the droplet diameters of 149, 69, 47, and 27 µm 
respectively. In each case, droplets were smaller than their orifices preventing surface 
wetting. To generate droplets in dripping regime, 𝑄𝑐/𝑄𝑑 was 3.6-12.5 and 𝑄𝑑 was gradually 
reduced with reducing orifice size to prevent too high velocity of the dispersed phase at the 
orifice that would cause transition from dripping to widening jetting.  
 
 
Figure 4. High speed camera stills of droplet generation showing variation of droplet size 
with orifice size: (a) Qd = 1.5 ml h-1, Qc = 8 ml h-1, Do = 200 μm, Dd = 144 μm; (b) Qd = 0.25 
ml h-1, Qc = 0.9 ml h-1, Do = 100 μm, Dd = 69 μm; (c) Qd = 0.1 ml h-1, Qc = 0.5 ml h-1, Do = 70 
μm, Dd = 47 μm; (d) Qd = 0.02 ml h-1, Qc = 0.25 ml h-1, Do = 40 μm, Dd = 27 μm. The scale 
bar displayed is the same for all figures. The dispersed phase is 1 wt% PLA/nanoclay in ethyl 
acetate. 
 
Nanoparticle filtration. A decrease in PLA to nanoclay ratio from 98/2 to 96/4 resulted in 
aggregation of nanoclay particles and a particle trapping in the dispersed phase in front of the 
orifice at low dispersed phase flow rates. An increase in the dispersed phase flow rate from 
0.5 to 3 ml h-1 suppressed the particle trapping, as shown in Figs. 5(a.4-5). A VOF-CSF 
numerical model was developed to further study the drop generation behavior and get an in-
depth understanding of the underlying physics behind the trapping of particles at variable 𝑄𝑑 
values. The numerical model was validated against experimental data for the generation of 
W/O/W emulsions in glass capillary devices.42,43 The validation of the numerical model with 
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current experiments with O/W emulsions is provided in Figure 5 (a.1&2 and b.1&2). It can be 
seen that the numerical model is capable of reproducing the experimental behavior accurately.  
  
Figure 5. A qualitative comparison of the experimental and numerical drop generation 
behaviour. (a.1&2): 1%PLGA in ethyl acetate (a.1) Qc= 6 ml/h, Qd = 1.5 ml/h; (a.2) Qc= 5 
ml/h, Qd = 0.5 ml/h; (a.3-5): 1% PLA/nanoclay (w:w=96:4); (a.3) Qc= 10 ml/h, Qd = 0.2 ml/h; 
(a.4) Qc= 10 ml/h, Qd = 0.5 ml/h; (a.5) Qc= 10 ml/h, Qd = 3 ml/h. The numerical images in 
Figures (b.3), (b.4) and (b.5) include flow vectors (upper half) and vorticity magnitude 
contours (lower half). 
 
Figures 5 (b.3-5) show the vorticity magnitude contours and flow vectors at the entrance of 
the collection tube at different 𝑄𝑑 values, corresponding to Figs. 5 (a3-5). In each frame, the 
upper part shows flow vectors and the lower part shows vorticity magnitude contours. 
Vorticity is the measure of a fluid element rotation as it moves in flow field, and is defined as 
(a.1) (b.1) (a.2) (b.2)
(a.3) (a.4) (a.5)
(b.3) (b.4) (b.5)
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the curl of velocity vector: ξ = ∇ × U��⃗ . Therefore, the vorticity magnitude |ξ|, is the magnitude 
of velocity vector curl, �∇ × U��⃗ �.44 At low dispersed phase flow rate of 𝑄𝑑= 0.2 ml h-1 (Figure 
5.a3 and b3), a very strong vortex flow forms in front of the orifice, which prevents the 
entrance of nanoparticles through the orifice. By increasing 𝑄𝑑 from 0.2 to 0.5 to 3 ml h
-1, the 
vortex flow strength decreases, which results in a reduction of vorticity magnitude and 
suppression of the filtration effect, so that progressively higher proportion of nanoparticles 
can pass through the orifice. The presence of strong vortex flow at low 𝑄𝑑 is a consequence 
of the high velocity gradient at the liquid-liquid interface. As 𝑄𝑑 increases, the velocity 
gradient is reduced causing the vortices to weaken. The particles closer to interface can enter 
the orifice easier than the particles further away from the interface. It can be explained by a 
higher level of shearing in the interfacial region than in the bulk of the dispersed phase flow. 
Movies (2-4) in supporting information show this phenomenon.  
A particle trapping phenomenon shown in Figure 5 can be used to achieve a continuous 
passive separation of nanoparticles from fluid streams. It differs from inertial particle 
separation in a Vortex Chip consisted of multiple expansion-contraction reservoirs,45,46 as 
hydrodynamic flow focusing does not require a prior stage of particle alignment by inertial 
focusing. A passive separation of nanoparticles by microfluidic flow focusing has the 
advantage over traditional filtration of exploiting orifice which is significantly larger than the 
particles and therefore, not prone to clogging. It eliminates the need for frequent backwashing 
and maintenance shutdowns which are common in filtration processes.  
Particle production from emulsions. Figure 6 shows images of different particles 
(nanoclay/PLGA, nanoclay/PLA, PLGA and PLA) produced by evaporation of ethyl acetate 
 20 
or DCM from droplets. The morphology and size of the particles depend on the dispersed 
phase composition and the initial droplet size. However, in each case, produced particles 
exhibited high size uniformity. 
 
Figure 6. Monodispersed microparticles produced by evaporation of DCM or ethyl acetate 
from the generated droplets: (a) nanoclay embedded PLGA particles with Dp = 20 µm; (b) 
nanoclay embedded PLA particles with Dp = 40 µm; (c) plain PLGA particles with Dp = 16 
µm; (d) plain PLA particles with Dp = 22 µm. 
 
Effect of Dispersed Phase Composition. The size of the particles produced after complete 
solvent evaporation can be predicted from a material balance equation for non-volatile solids 
(polymer and nanoclay) in the dispersed phase. If the particles are nonporous, their volume 𝐶𝑝 
and diameter 𝐷𝑝 are proportional to the initial volume 𝐶𝑑 and diameter 𝐷𝑑 of the droplets:
41  
𝐶𝑝 = 𝑥𝑝𝜕𝑑𝜕𝑝 𝐶𝑑                                                                       (11) 
𝐷𝑝 = �𝑥𝑝𝜕𝑑𝜕𝑝3 𝐷𝑑                                                                   (12) 
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where 𝑥𝑝 is the mass fraction of non-volatile solids (polymer and nanoclay) in the dispersed 
phase, and 𝜕𝑝 and 𝜕𝑑 are the densities of the particles and droplets, respectively. Figure 7 
shows the relationship between 𝐷𝑝 and 𝐷𝑑 for plain PLGA and PLA particles. The solid lines 
are the lines of best-fit to the experimental data, while the dotted lines correspond to Eq. (12), 
with their gradients equal to �𝑥𝑝𝜕𝑑 𝜕𝑝⁄
3 .   
 
Figure 7. The particle diameter vs. droplet diameter for plain polymeric particles: (a) PLGA; 
(b) PLA. The dispersed phase formulation:  0.5% PLGA in EA,  1% PLGA in EA,  2% 
PLGA in EA,  1% PLA in DCM, and  1% PLA in EA. The solid lines are the best fit to 
the experimental data, while the dotted lines satisfy Eq. (12).  
 
As predicted by Eq. (12), 𝐷𝑝 is directly proportional to 𝐷𝑑 for all formulations, with small 
deviations between the experimental and theoretical results for both polymers and solvents 
(DCM and EA). Figure 7 reflects the ability of the process to precisely tune the particle size 
over a wide range of 4-30 µm, whilst maintaining high particle size uniformity. Particles that 
are 4 µm are considered suitable for intravenous drug administration since the smallest 
capillary blood vessels have a diameter of about 7 µm.47 Particles in the size range of 10-30 
µm are suitable for parenteral drug delivery via subcutaneous or intramuscular injection.48  
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As expected, the particle size increased with increasing the polymer concentration 𝑥𝑝, which 
can be seen in Figure 7(a) for PLGA particles at 𝑥𝑝 = 0.5-2 wt%. Under the same conditions, 
PLGA particles are smaller than PLA particles (Figures 7 (a) and (b) for 1 wt% polymer in 
EA), since particle diameters are inversely proportional to the cubed root of particle densities 
and the density of PLGA (1.34 g cm-3) is higher than that of PLA (1.24 g cm-3). The effect of 
solvent type on the particle size can be seen in Figure 7(b), which compares the size of PLA 
particles produced using the same polymer concentration in the dispersed phase (1 wt%), but 
different solvents (EA and DCM). Smaller particles were produced using EA, due to the 
lower density of EA (0.902 g cm-3) as compared to DCM (1.33 g cm-3).  
In Figure 7, a minor deviation between experimental particle sizes and their theoretical 
estimates is a result of pore formation in the polymer matrix, which was not accounted for in 
the material balance equation (Eq. 11). The particle porosity can be estimated from the ratio 
of the gradients of the theoretical and experimental 𝐷𝑝 vs. 𝐷𝑑 lines:
13   
𝜀 = 1 − � ( )( )  ∂∂ ∂∂ expdp theordp DD DD �
3                                                                  (13) 
Solvent choice can also affect the porosity of particles, as can be seen in Figure 7(b). The 
porosity of PLA particles produced using DCM and EA was 14.8 and 25.5 % respectively, 
estimated from Eq. (13). At 20 °C, water is more soluble in EA (3.3 wt%) than in DCM (0.24 
wt%).49 The higher the solubility of water in the organic phase, the higher the amount of 
water taken up by the droplets and the higher the porosity of the particles after solvent 
evaporation, which is similar to the effect of internal water in W/O/W emulsion.13 Therefore, 
apart from phase flow rates and polymer concentration, densities of the polymer and solvent 
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and water solubility in the organic phase also play a significant role in the control of particle 
size and porosity.  
Nanoclay-Embedded Polymer Particles. Figure 8 shows the effect of nanoclay on the particle 
size for the dispersed phase containing PLA in DCM (red symbols) and PLGA in EA (black 
symbols). The solid lines are the trend lines for nanoclay embedded particles, the dashed lines 
are the trend lines for plain polymeric particles, while the dotted lines satisfy Eq. (12). For 
PLA in DCM, the 𝐷𝑝 vs. 𝐷𝑑 lines have higher gradients, due to higher density of DCM 
compared to EA. In the absence of swelling effects and particle porosity, all lines for the 
same polymer and solvent should coincide, irrespective of the presence of nanoclay (due to 
small amount of nanonclay in the polymer matrix), which is not the case in Figure 8.  
 
Figure 8. The particle diameter vs. droplet diameter for nanoclay embedded and plain 
polymeric particles:  Nanoclay embedded PLA,  Plain PLA,  Nanoclay embedded 
PLGA,  Plain PLGA. The PLA solvent was DCM and the PLGA solvent was EA. The 
polymer concentration was 1 wt% and the polymer/nanoclay mass ratio was 98:2. The solid 
lines are the trend lines for nanoclay embedded particles, the dashed lines are the trend lines 
for plain polymeric particles, while the dotted lines satisfy Eq. (12).  
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 A higher deviation of experimental particle diameters from their values predicted by Eq. (12) 
was observed for both nanoclay embedded polymers, as compared to plain particles. It can be 
explained by either higher porosity or higher degree of swelling of nanoclay-loaded particles 
compared to plain polymer particles.  
 
Figure 9. FIB cross-sections of: (a) PLA particle showing pores in the polymer network; (b) 
nanoclay embedded PLA particles with non-porous internal structure. Scale Bars: 5 µm. 
 
FIB cross-sectioned images of PLA particles shown in Figure 9 indicate that nanoclay-
embedded PLA particles are significantly less porous than those produced without nanoclay. 
When placed in contact with water, montmorillonite can adsorb up to 10 g H2O/g clay, which 
can increase its volume by up to 20 times50. The exact degree of swelling depends on the type 
of exchangeable cation. Although montmorillonites cation-exchanged with quaternary 
ammonium cations are primarily swollen by organic solvents, they can adsorb up to 400 mg 
H2O/g clay.51 This water uptake increases the size of the particles and makes the polymer 
matrix more compact and less permeable to gases.52 Hence, a compact structure of 
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nanoclay/PLA particle in Figure 9b is an evidence of the presence of nanoclay in the polymer 
matrix and the XRD plot shown in Figure 10 provides another evidence.  
 
Figure 10. XRD plot of nanoclay powder, PLA/nanoclay particles and plain PLA particles. 
 
The amorphous nature of pure poly(DL-lactic acid) is confirmed in Figure 10 by a broad 
amorphous ‘hump’ over a wide 2Ө range of 10-30°, due to X-rays being scattered in many 
directions. In contrast, high intensity narrower peaks were observed in the XRD pattern of 
pure crystalline nanoclay powder. Nanoclay embedded polymer particles exhibit crystal peaks 
at similar positions as pure nanoclay (2Ө=5°, 20°, 30° and 35°), in addition to a wide hump 
part, which serves as an evidence of the embedment of nanoclay in the polymer matrix.  
Golf-Ball Like Polymer Particles. The effects of introducing a polymer non-solvent 
(hydrocarbon porogen) in the dispersed phase are shown in Figure 11. Particles formed by 
phase separation within the droplets consisted of 1 wt% [2-methylpentane/PLA 30/70 (w/w)] 
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in DCM are shown in Figure 11(a)-(c). During DCM evaporation, the droplets of 2-
methylpentane, since immiscible with PLA and less volatile than DCM, tend to 
heteroaggregate on the surface of PLA-laden evaporating droplets (see Figure 1c).11 This 
brings about dimples, which are ‘footprints’ formed by droplets of the non-solvent on the 
surface of the PLA particle. Also, pores can be seen in the FIB cross section shown in Figure 
11 (d), which are the result of phase separation between the polymer and the non-solvent. 
However, when the same emulsion was produced with gentle stirring in the collection vial, 
smaller dimples were formed on the surface of particles as shown in Figure 11(e) and (f). In 
this case, the droplets of the non-solvent detach earlier from the surface, thereby, inducing 
formation of smaller dimples on the surface. Pores are also noticeable in the particle cross 
section created by FIB (Figure 11g), since stirring does not affect the migration rate of inner 
droplets to the surface but only the rate of their detachment from the particle surface.  
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Figure 11. SEM images of dimpled PLA particles. The dispersed phase was: (a-g) 1 wt% [2-
methylpentane/PLA (w:w=3:7)] in DCM without stirring (a-d) and with stirring (e-g) of the 
formed emulsion; (h-i) 10 wt% % [2-methylpentane/PLA (w:w=3:7)] in DCM. Scale bars: (a-
b) 20 µm (c) 9 µm (d) 6 µm (e) 20 µm (f) 4.5 µm (g) 44 µm (h) 44 µm (i) 50 µm. 
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When 10 wt% [2-methylpentane/PLA(w:w=3:7)] in DCM was used as a dispersed phase with 
gentle stirring in the collection vial, microspheres with rougher surface were obtained, as 
shown in Figure 11(h) and (i). Higher particle porosity in Figure 11(i) can be attributed to the 
higher percent of non-solvent in the dispersed phase, as compared to that in Figure 11 (a-g). 
Therefore, the variation in the amount of polymer and non-solvent could serve as a means of 
adjusting particle porosity and surface roughness. Surface dimples can act as picoliter 
beakers,11 but can also enhance cell adhesion53 and particle mobility and dispersibility in 
fluids, due to Magnus effect and minimised contact area. It is important if the fabricated 
particles are intended to be used as carriers in dry powder inhaler formulations.54  
Drug Release from Particles. The release patterns of paracetamol from the fabricated 
particles are shown in Figure 12. Increasing the diameter of plain PLGA particles from 17 µm 
(Figure 12a) to 45 µm (Figure 12b) reduced cumulative drug release after 1 h from 100 to 80 
% with the remaining 20 % released over 140 h. It is generally accepted that higher surface 
area per unit volume leads to higher degradation rate of the polymer matrix. As shown in 
Figure 12(a), replacing PLGA with PLGA/nanoclay (98:2 w/w) in the dispersed phase further 
reduced paracetamol release, as a result of greatly increased drug diffusion path length due to 
the obstacles imposed by the impervious clay platelets. The relative permeability of polymer 
matrix depends on the volume fraction of the nanofiller in the host polymer, the aspect ratio 
of the platelets and their orientation.52 Improvement in drug release control is also observed in 
Figure 12b, which shows that the initial burst of drug release can be completely eliminated by 
incorporating nanoclay in the polymer matrix.  
 29 
 
Figure 12. Release of paracetamol from microparticles: (a) ∆ 17-µm plain PLGA, ▲ 17-µm 
PLGA/nanoclay; (b)  45-µm plain PLGA,  45-µm PLGA/nanoclay. The continuous 
phase: 5 wt% PVA in water saturated with ethyl acetate; (c)  25-µm golf ball-like PLA,  
25-µm plain PLA. The continuous phase: 5 wt% PVA in water. The dispersed phase used for 
production of plain PLGA and PLA particles: 2 wt% PLGA and 1 wt% PLA in ethyl acetate, 
respectively. The initial drug loading in dried particles: 5 wt%. The error bars represent one 
standard deviation of the means based on 3 repeated measurements.  
 
Furthermore, the amount of drug released after 1 h from plain 25-µm PLA particles (Figure 
12c) was lower than that from plain 45-µm PLGA particles (Figures 12b), although in the 
former case both the initial polymer concentration in the dispersed phase and the particle size 
was lower. It is expected because PLGA typically exhibits a faster degradation than PLA.49 
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PLA is more hydrophobic than PLGA due to extra methyl groups in glycolide residues and 
the ester bonds of PLA are less prone to hydrolysis due to steric hindrance. Furthermore, 
PLGA 50:50 used in this work has the fastest degradation rate among all PLGA copolymers. 
Figure 10c shows that the drug release rate from golf-ball-shaped PLA particles was higher 
than that from plain PLA particles of the same size, which can be attributed to the higher 
porosity of dimpled particles, due to the presence of non-solvent in the dispersed phase. More 
porous polymer matrix makes it easier for water molecules to penetrate inside the particles, 
which results in faster polymer degradation and drug release.  
The release rate of paracetamol in Fig. 12 is very high as a result of the high solubility of 
paracetamol in water (17.4 g/kg) and high solubility of ethyl acetate in water (8.3 %). 
Irrespective of the fast release profiles, the rate of drug release was precisely controlled by the 
microstructure of the particles.  
Janus and Hemispherical Polymer Particles. Biodegradable PLA-PCL Janus particles were 
formed by solvent evaporation-induced internal phase separation from emulsion droplets 
composed of 3 % (v/v) PCL/PLA mixture (30/70 or 70/30) dissolved in DCM. Confocal 
microscopic images of Janus particles stained with Rh6G and Nile Red are shown in Figure 
13. The fluorescence emission spectrum of Rh6G is in the range from ≈500-700 nm (green to 
red visible range) and that of Nile red is above 550 nm (mainly visible red fluorescence 
range). Therefore, green emission captured by photomultiplier tube 1 (PMT1) at 515±30 nm 
should reveal the presence of Rh6G. When PLA and PCL films are stained with Rh6G, only 
PLA film exhibits green fluorescence. A strong preferential sorption of Rh6G onto PLA was 
successfully utilized to identify and visualize the portions of the particles with the presence of 
PLA. As shown in the inset image in Figures 13 (b) and (e), bright green regions occupy 
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respectively 1/3 and 2/3 of the total particle area, corresponding to the proportion of PLA in 
the polymer mixture. It shows that phase separation within the droplets was complete with 
only trace amounts of PLA present in PCL portions and vice versa. Nile red binds non-
specifically to both polymers, resulting in red fluorescence of entire Janus particle (Figure 13 
c and f). However, PLA portions exhibit a brighter shade of red, due to contribution from 
both Nile red and Rh6G to the total light emission. The preferential sorption observed here 
for the model drug Rh6G could be utilized for controlled drug loading as proportions of 
constituent polymers in the formulation can be varied in a controlled fashion. Also, co-
encapsulation of drugs could be possible since a second drug with high affinity for PCL could 
be introduced to effect simultaneous controlled release of two drugs. The release pattern can 
be controlled by the rate of degradation of the constituent polymers. The degradation 
properties could be harnessed to achieve multiple site drug delivery, e.g. particles produced 
from combination of a low and high pH soluble polymer would deliver drugs to gastric and 
enteric regions respectively from a single dose.  
 32 
 
Figure 13. Confocal microscopic images of Janus PLA-PCL particles: (a)-(c) 30:70 (v/v) 
PLA/PCL ratio; (d)-(f) 70/30 (v/v) PLA/PCL ratio; (a) and (d) Optical images; (b) and (e) 
PMT1 images (emission 515±30 nm); (c) and (f) PMT2 images (emission above 570 nm). 
Scale bar: 50μm on (a) applies for (a)-(c); 50 μm on (d) applies for (e)-(f). 
 
SEM images of monodispersed Janus particles are shown in Figure 14a. Uniform dome-
absent hemispherical PCL particles formed by the dissolution of the PLA dome (i.e 
hemispherical cap) by acetone are shown in Figure 14b. These particles are formed because 
amorphous PLA is more soluble in acetone than PCL. The size of hemispherical particles can 
be tuned by changing the volume ratio of the solvent resistant polymer in Janus particles. 
Consequently, the dissolved polymer which can be recovered and reused, acts as a size and 
shape adjustment tool. The unique morphology of Janus and hemispherical particles can also 
be exploited for unique release properties when these particles are used as drug vehicles.  
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Figure 14. (a) SEM images of Janus particles with 30/70 (v/v) PLA/PCL. Dissolution of PLA 
dome results in hemispherical PCL particles shown in (b). Scale bar: (a) 50 μm (b) 10 μm. 
 
CONCLUSIONS 
Synthetic polymer biodegradable microparticles with tunable size, shape, internal structure 
and surface roughness were produced by counter-current flow focusing in 3-D glass capillary 
devices. The microstructure of the particles was tailored by the addition of nanoclay, polymer 
non-solvent (porogen) or a second polymer in the dispersed phase prior to emulsification. The 
polymer matrix was found to be less porous or more porous as a result of the addition of 
nanoclay or 2-methylpentane, respectively, which proved to have profound effects on the 
release rate of paracetamol. Surface dimples which can enhance particle mobility in air and 
cell adhesion properties were created by adding 2-methylpentane to the dispersed phase. The 
size and shape of the dimples and the particle porosity were adjusted by the rate of stirring in 
the collection vial and the concentration of non-solvent and polymer in the dispersed phase. 
Numerical modelling of fluid flow for nanoclay-loaded droplets revealed the trapping of 
nanoparticles in the dispersed phase at low flow rates due to vortex formation upstream of the 
orifice. The phenomenon of microvortex-based particle trapping can be exploited for passive 
separation of nanoparticles from fluid streams.  
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Janus PLA/PCL particles were produced by emulsifying PLA/PCL blends (30/70 or 70/30) 
dissolved in dichloromethane and subsequent internal phase separation induced by solvent 
evaporation. A strong preferential sorption of Rhodamine 6G fluorescence dye onto PLA was 
successfully utilized to identify PLA portions of the Janus particles by CLSM. This could be 
exploited for modified drug release by polymer content variation, drug co-encapsulation and 
multiple site drug delivery. Uniform hemispherical PCL particles were obtained by 
dissolution of PLA domes with acetone. The dissolved polymer, which can be recovered and 
reused, acts as a size and shape adjustment tool and the increased surface area and non-
spherical shape can be exploited for unique drug release properties. 
Glass capillary devices were found to be extremely useful tool for preparation of polymeric 
microspheres with versatile morphology and structure. The particle size can easily be 
controlled by orifice size of collection capillary and flow rates and physical properties of both 
phases without orifice wetting, clogging or swelling problems.  
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